MedTrace Logo

Safety and Effectiveness of Giving Adefovir Dipivoxil Plus Abacavir Plus Efavirenz Plus Amprenavir to HIV-Infected Patients Who Have Failed to Respond to Previous Protease Inhibitor Treatment

NCT00002419 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe and effective to give adefovir dipivoxil plus abacavir (ABC) plus efavirenz (EFV) plus amprenavir (APV) to HIV-infected patients who have failed to respond to previous treatment with protease inhibitors (PIs).

Conditions

  • HIV Infections

Interventions

DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Efavirenz

DRUG

Adefovir dipivoxil

Sponsors & Collaborators

  • Glaxo Wellcome

    collaborator INDUSTRY

  • Dupont Applied Biosciences

    collaborator INDUSTRY

  • Gilead Sciences

    lead INDUSTRY

Study Design

Purpose
TREATMENT

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002419 on ClinicalTrials.gov